‘Toujeo,’ next-generation basal insulin, has been approved, competing against ‘Tresiba’

A number of next-generation long-acting basal insulin, which decreased risks in hypoglycemia occurrence, is about to enter the domestic market.

According to the industry concerned on the 14^th, Sanofi-Aventis’s next-generation basal insulin, ‘Toujeo Solostar(insulin glargine)’ has acquired approval from the Ministry of Food and Drug Safety.

Toujeo, widely known by its code name, U300, is long-...